세계의 부신 부전 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 치료별, 투여 경로별, 유통 경로별, 지역별, 경쟁별(2020-2030년)
Adrenal Insufficiency Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Route of Administration, By Distribution Channel By Region and Competition, 2020-2030F
상품코드:1728162
리서치사:TechSci Research
발행일:2025년 05월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 부신 부전 시장은 2024년 3억 5,621만 달러로 평가되었고, 2030년까지 연평균 성장률(CAGR) 8.86%로 성장할 것으로 예측됩니다.
부신 기능 부전은 부신의 부적절한 코티솔 생산으로 인해 발생하는 심각한 내분비 장애로, 치료하지 않으면 생명을 위협할 수 있습니다. 이 시장은 이 질환을 관리하기 위한 진단 도구, 치료적 개입 및 보조 치료법을 포함합니다. 자가 면역 질환, 감염, 장기간의 글루코코르티코이드 사용과 관련된 인식의 증가, 진단 능력의 향상, 발병률의 증가가 시장 확대에 기여하고 있습니다. 2024년에 보고된 바와 같이, 장기 스테로이드 치료를 받는 환자에서 부신 기능 부전이 종종 발생하여 효과적인 치료 경로와 조기 의료 개입의 필요성이 강조되고 있습니다. 이러한 변화하는 환경은 전 세계적으로 예방 및 개인 맞춤형 의료 솔루션에 대한 강력한 수요를 촉발시켰습니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
3억 5,621만 달러
시장 규모(2030년)
5억 8,814만 달러
CAGR(2025-2030년)
8.86%
급성장 부문
글루코코르티코이드
최대 시장
북미
시장 성장 촉진요인
부신 부전의 유병률 증가
주요 시장 과제
진단의 복잡성
주요 시장 동향
유전자 검사 및 개인 맞춤형 의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 부신 부전 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
유형별(1차, 2차, 3차)
치료별(글루코코르티코이드, 코르티코트로핀, 기타)
투여 경로별(경구, 주사, 기타)
유통 경로별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
유형별
치료별
투여 경로별
유통 경로별
지역별
제5장 아시아태평양의 부신 부전 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
유형별
치료별
투여 경로별
유통 경로별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 부신 부전 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 부신 부전 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 부신 부전 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 부신 부전 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
이집트
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
합병과 인수
제12장 세계의 부신 부전 시장 : SWOT 분석
제13장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Acrotech Biopharma, Inc.
Bausch Health, Canada Inc
AdvaCare Pharma
Weefselpharma
Cipla Inc.
Pfizer Inc
Wellona Pharma
Eugia US
Sandoz Inc.
Prevego Healthcare & Research Pvt Ltd.
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
영문 목차
영문목차
The Global Adrenal Insufficiency Market was valued at USD 356.21 million in 2024 and is expected to grow at a CAGR of 8.86% through 2030. Adrenal insufficiency is a serious endocrine disorder resulting from inadequate cortisol production by the adrenal glands, which can be life-threatening if untreated. The market encompasses diagnostic tools, therapeutic interventions, and supportive treatments for managing this condition. A rise in awareness, improved diagnostic capabilities, and growing incidence linked to autoimmune disorders, infections, and prolonged glucocorticoid use are contributing to market expansion. As reported in 2024, adrenal insufficiency often emerges in patients on long-term steroid therapy, underlining the need for effective treatment pathways and early medical intervention. This evolving landscape has sparked robust demand for both preventive and personalized healthcare solutions worldwide.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 356.21 Million
Market Size 2030
USD 588.14 Million
CAGR 2025-2030
8.86%
Fastest Growing Segment
Glucocorticoid
Largest Market
North America
Key Market Drivers
Increasing Prevalence of Adrenal Insufficiency
The growing incidence of adrenal insufficiency is a primary driver of market growth. This chronic condition results from inadequate cortisol production and is frequently associated with autoimmune diseases, prolonged steroid use, and infections that impact adrenal function. According to the National Institutes of Health, adrenal insufficiency now affects an estimated 150 to 280 individuals per million. Rising cases of Addison's disease and secondary adrenal insufficiency linked to pituitary dysfunction are increasing the number of patients requiring diagnosis and long-term hormone replacement therapy. Infections and medication-induced adrenal suppression are also contributing to the growing patient pool, emphasizing the need for accessible and effective treatment solutions.
Key Market Challenges
Diagnostic Complexity
The complexity of diagnosing adrenal insufficiency remains a major barrier to market growth. The condition manifests through diverse symptoms-such as fatigue, hypotension, gastrointestinal discomfort, and psychological disturbances-which often overlap with other medical issues, leading to delayed or missed diagnoses. Differentiating between primary, secondary, and tertiary adrenal insufficiency adds further difficulty due to varied underlying causes, including adrenal gland damage, pituitary malfunction, or hypothalamic dysfunction. Accurate diagnosis requires specific hormonal testing and interpretation, making it reliant on specialized clinical expertise and advanced laboratory infrastructure. These diagnostic challenges limit timely intervention and contribute to underdiagnosis, particularly in resource-constrained healthcare systems.
Key Market Trends
Genetic Testing and Personalized Medicine
The integration of genetic testing and personalized treatment approaches is emerging as a transformative trend in adrenal insufficiency care. Genetic screening enables early identification of hereditary or mutation-related causes of cortisol deficiency, streamlining diagnosis and informing targeted therapeutic strategies. This personalized approach supports better clinical outcomes by customizing glucocorticoid replacement therapies to individual patient needs, optimizing dosing, and minimizing adverse effects. The broader trend toward precision medicine is accelerating the adoption of advanced diagnostics in endocrine disorders, with genetic insights playing a key role in differentiating adrenal insufficiency subtypes and refining long-term treatment plans.
Key Market Players
Acrotech Biopharma, Inc.
Bausch Health, Canada Inc
AdvaCare Pharma
Weefselpharma
Cipla Inc.
Pfizer Inc
Wellona Pharma
Eugia US
Sandoz Inc.
Prevego Healthcare & Research Pvt Ltd
Report Scope:
In this report, the Global Adrenal Insufficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Adrenal Insufficiency Market, By Type:
Primary
Secondary
Tertiary
Adrenal Insufficiency Market, By Treatment:
Glucocorticoid
Corticotropin
Others
Adrenal Insufficiency Market, By Route of Administration:
Oral
Injectables
Others
Adrenal Insufficiency Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Adrenal Insufficiency Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Adrenal Insufficiency Market.
Available Customizations:
Global Adrenal Insufficiency Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Adrenal Insufficiency Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Type (Primary, Secondary, Tertiary)
4.2.2. By Treatment (Glucocorticoid, Corticotropin, Others)
4.2.3. By Route of Administration (Oral, Injectables, Others)
4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.5. By Region
4.2.6. By Company (2024)
4.3. Market Map
4.3.1. By Type
4.3.2. By Treatment
4.3.3. By Route of Administration
4.3.4. By Distribution Channel
4.3.5. By Region
5. Asia Pacific Adrenal Insufficiency Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Treatment
5.2.3. By Route of Administration
5.2.4. By Distribution Channel
5.2.5. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Adrenal Insufficiency Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Type
5.3.1.2.2. By Treatment
5.3.1.2.3. By Route of Administration
5.3.1.2.4. By Distribution Channel
5.3.2. India Adrenal Insufficiency Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Type
5.3.2.2.2. By Treatment
5.3.2.2.3. By Route of Administration
5.3.2.2.4. By Distribution Channel
5.3.3. Australia Adrenal Insufficiency Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Type
5.3.3.2.2. By Treatment
5.3.3.2.3. By Route of Administration
5.3.3.2.4. By Distribution Channel
5.3.4. Japan Adrenal Insufficiency Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Type
5.3.4.2.2. By Treatment
5.3.4.2.3. By Route of Administration
5.3.4.2.4. By Distribution Channel
5.3.5. South Korea Adrenal Insufficiency Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Type
5.3.5.2.2. By Treatment
5.3.5.2.3. By Route of Administration
5.3.5.2.4. By Distribution Channel
6. Europe Adrenal Insufficiency Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Treatment
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. Europe: Country Analysis
6.3.1. France Adrenal Insufficiency Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Treatment
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Germany Adrenal Insufficiency Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Treatment
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Spain Adrenal Insufficiency Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Treatment
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
6.3.4. Italy Adrenal Insufficiency Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Type
6.3.4.2.2. By Treatment
6.3.4.2.3. By Route of Administration
6.3.4.2.4. By Distribution Channel
6.3.5. United Kingdom Adrenal Insufficiency Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Type
6.3.5.2.2. By Treatment
6.3.5.2.3. By Route of Administration
6.3.5.2.4. By Distribution Channel
7. North America Adrenal Insufficiency Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Treatment
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Adrenal Insufficiency Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Treatment
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Adrenal Insufficiency Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Treatment
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Adrenal Insufficiency Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Treatment
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. South America Adrenal Insufficiency Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Treatment
8.2.3. By Distribution Channel
8.2.4. By Route of Administration
8.2.5. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Adrenal Insufficiency Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Treatment
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Argentina Adrenal Insufficiency Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Treatment
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Colombia Adrenal Insufficiency Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Treatment
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
9. Middle East and Africa Adrenal Insufficiency Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Treatment
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Adrenal Insufficiency Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Treatment
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. Saudi Arabia Adrenal Insufficiency Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Treatment
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. UAE Adrenal Insufficiency Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Treatment
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. Egypt Adrenal Insufficiency Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Treatment
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Adrenal Insufficiency Market: SWOT Analysis
